AUA2019 027IC AUA CRPC Guidelines And Therapeutic Advances In Metastatic Prostate Cancer

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-and-therapeutic-advances-metastatic Instructional Course Director(s) Michael Cookson, MD, MMHC Professor and Chair University of Oklahoma Instructional Course Faculty(s) David Jarrard, MD University of Wisconsin Adam Kibel, MD Brigham Health, Harvard University William Lowrance, MD University of Utah, Huntsman Cancer Institute This course will review the important and newly updated 2018 AUA Guidelines on Castration-Resistant Prostate Cancer. This includes a thorough discussion of new trials and approval of agents for MO non-metastatic nmCRPC. In addition, we will review therapeutic breakthroughs in the management of advanced and metastatic hormone naïve prostate cancer (mHSPPC). Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines. Also, the role of genomic classifiers and genetic testing in the evaluation of CRPC, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA CRPC guidelines in those instances. This course will be a benefit to practicing urologists, oncologists, advanced practice providers, and residents/fellows preparing for their certification exam and physicians preparing for their re-certification exam. Learning Objectives: Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC Understand the sequencing and indications for active treatment with approved agents in the management of nmCRPC Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice Understand and analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer